Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
VK Acquisitions VI
Greenwich, Connecticut, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
VK Acquisitions VI is a specialized investment vehicle and subsidiary of Viking Global Investors, a leading global investment firm. The entity is primarily utilized as a holding company or acquisition vehicle for strategic investments within the healthcare and life sciences sectors. It gained prominence through its role in the 2023 acquisition and subsequent take-private transaction of Kinnate Biopharma, a clinical-stage precision oncology company. As a financing and acquisition arm, it facilitates the deployment of capital into high-growth biotechnology and pharmaceutical assets.
- Industry
- Investors
Beyond the preview
Go deeper on VK Acquisitions VI.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VK Acquisitions VI.